

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/540139

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056340 A2

- (51) International Patent Classification⁷: A61K 9/14
- (21) International Application Number:
PCT/EP2003/014740
- (22) International Filing Date:
22 December 2003 (22.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
MI2002A002748
23 December 2002 (23.12.2002) IT
- (71) Applicant (for all designated States except US): EURAND S.P.A. [IT/IT]; Via Martin Luther King 13, I-20060 Pesano Con Bornago (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): COLOMBO, Italo [IT/IT]; Via Don Sturzo, 15, I-20065 Inzago (IT). GERVASONI, Dario [IT/IT]; Via Alberti 8, I-20061 Carugate (IT).
- (74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria 9, I-20122 Milan (IT).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABILISED SOLID DRUG DISPERSIONS IN AN ORGANIC CARRIER AND A PROCESS FOR PREPARING THE SAME

(57) Abstract: New solid drug dispersions are described in which the drug is present in amorphous form and massively dispersed (in bulk) inside the particles of an organic carrier selected from cross-linked polymers and/or a complexing agents. These dispersions are obtainable by mixing together the drug and the carrier and applying an oscillating electromagnetic field to the mixture, to a frequency belonging to the microwave region; the microwaves are applied according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes. With respect to the known techniques, the present invention allows to increase in the amount of drug incorporated into the carrier in amorphous form, and to increase the physical stability of the amorphous phase. This is particularly useful in the preparation of pharmaceutical compositions based on drugs which are crystalline in nature, such as are notoriously sparingly soluble in water: thanks to the increased amounts and stability of the drug in amorphous form, the resulting formulations have a more rapid and intense effect, and are endowed with greater bioavailability.

STABILISED SOLID DRUG DISPERSIONS IN AN ORGANIC CARRIER AND A PROCESS FOR PREPARING THE SAME

FIELD OF THE INVENTION

The present invention refers to the field of rapid effect pharmaceutical compositions provided with high bioavailability. The preparation of new drug-carrier composites (stabilised solid dispersions) is described in which the drug is massively dispersed (in bulk) in amorphous form inside an organic carrier.

PRIOR ART

The attainment of ready to use pharmaceutical compositions, which ensure high solubilisation kinetics of the drug and therefore a high bioavailability immediately following administration, is an important objective in pharmaceutical technology; such a need is particularly felt in the case of drugs sparingly soluble in water, which notoriously have a low bioavailability.

Many drugs poorly soluble in water are present in the crystalline state: a system to improve the solubility of this group of drugs is that of destructuring the crystalline network, rendering them amorphous: in fact a substance in the amorphous state has both greater solubility and faster dissolution kinetics in water with respect to the corresponding crystalline state. The reason for which lies in the fact that whilst the dissolution of a crystal requires an additional intervention on the part of the solvent to break the intermolecular bonds in the crystalline network, such an intervention is not required in the case of the amorphous form: in the latter case the dissolution procedure requires less energy and the dissolution takes place more rapidly.

The amorphisation procedures for crystalline drugs have been known for a long time (Yu L., *Amorphous pharmaceutical solids: preparation characterisation and stabilization*. *Adv. Drug. Delivery Rev.*, 2001, 48, p. 27-42.). However, due to the greater stability of crystals, (a physical form with lower free energy and, therefore, thermodynamically more stable) the amorphised drugs have poor stability (metastable phase) and tend to easily recrystallise, thus losing their temporarily acquired increased solubility.

With the aim of limiting this phenomenon, it has been proposed to make the amorphous drug deposit on the pharmaceutical carriers: in this case, the drug-carrier interactive forces limit the tendency of the amorphous phase molecule to re-aggregate, which allows them to have a greater stability. To obtain that, "solvent deposition" procedures have been proposed, according to which the drugs are initially dissolved in an appropriate solvent; to this solution are added insoluble carrier particles, and then the solvent is evaporated, thus making the drug in amorphous form precipitate on the carrier.

These strategies however are only partially effective, in that they lead to not very high percentages of amorphisation; in addition, the drug remains deposited only on the external surface of the carrier particles i.e. not distributed internally (in bulk) inside the particles themselves (*International Journal of Pharmaceutics*, 33, 1986, p. 115-124): the drug lying on the surface still shows a notable freedom for re-aggregation easily forming crystalline structures. Recently, some authors (*Drug Dev. Ind. Pharm.*, 24(4), 1998, p.359-363) have proposed the use of microwaves to increase the solubility of crystalline drugs: the process provides the mixing of drug with an inorganic carrier with a high surface area (silicon dioxide), and exposure to microwaves; however, even in this case composites are obtained, denominated by the authors "*surface solid dispersions*", in which the amorphised drug is localised on the surface of the carrier particles. Even in this case the limitations of the previous systems are present, i.e. the drug is deposited only on the external surfaces of the carrier particles, and is therefore still subject to the phenomenon of re-crystallisation.

EP-A-1308156 describes the preparation of solid dispersions of a drug in water-soluble polymers, such as linear polyvinylpyrrolidone, the dispersion being obtained by microwave treatment. US-A-6462093 describes the microwave-assisted preparation of drug-carrier composites; the examples show the use, as carriers, of hydroxypropylmethylcellulose, its acetosuccinate derivative, and linear polyvinylpyrrolidone. In both these references the microwave power (Watt) is kept constant throughout the entire treatment.

Until present, none of the available amorphisation processes is entirely satisfactory. Aim of the present invention is to provide a highly effective process

capable to obtain both a high dispersion of the active principle throughout the carrier and also a high degree of amorphisation of the active principle.

SUMMARY

It has now been surprisingly found that when a drug is mixed with an organic carrier and then treated with an oscillating electromagnetic field at frequencies belonging to the microwave region according to a specific heating cycle, a drug-carrier composite is obtained in which the drug is amorphised in higher quantities and in more stable form, with respect to these obtained by the prior art.

In the present invention the treatment with microwaves is carried out on homogeneous mixtures of drug and carrier pre-wetted with appropriate quantities of solvents, or on drug-carrier mixtures in the dry state, placed on dielectric material based supports which couple with the microwaves, such as for example polytetrafluoroethylene loaded with graphite.

The microwave application cycle is such that the drug mixture is heated to a temperature higher than the melting temperature of the drug, and such temperature is subsequently maintained constant for at least 5 minutes. The composites obtained according to the present invention, herein identified as "stabilised solid dispersions", are characterised by containing a quantity of amorphised drug greater than 50 % by weight with respect to the total drug present, and by the fact that the drug is also dispersed inside (in-bulk) of the carrier particles, hence not just on the external surface of the same.

The present dispersion technique in-bulk of the drug in amorphous form is seen as being particularly effective and useful in the case of drugs poorly soluble in water, thus allowing the increase in the characteristics of solubility and bioavailability in rapid times following administration.

DESCRIPTION OF THE DRAWINGS

Figure 1: calibration lines for the Ibuprofen β -cyclodextrine, Ibuprofen Crosspovidone and Nifedipine Crosspovidone systems.

● : Ibuprofen / beta-Cyclodextrine

■ : Ibuprofen / Crosspovidone

▲ : Nifedipine / Crosspovidone

Figure 2: power (—) and temperature (—) profiles obtained during the treatment of the sample PVP/Nif01. (example 4, table 8).

Figure 3: power (—) and temperature (—) profiles obtained during the treatment of the sample PVP/Nim06 (example 4, table 8).

Figure 4: heating cycle applied in the production of composite PVP/Nif02 (example 1, table 5)

Figure 5: section of a particle of composite PVP/Nim02 (example 1, table 4) observed by scansion electronic microscope.

Figure 6: magnified image of the particle of figure 5, with analysis of drug concentration in three different points of the particle section.

DETAILED DESCRIPTION OF THE INVENTION

A first subject of the invention is constituted by new composites containing a drug dispersed in an organic carrier, in which the drug is:

- present in amorphous form in quantities greater than or equal to 50 % by weight with respect to the total of the drug present in the composite, and
- massively dispersed ("in-bulk") within the particles of the above mentioned carrier.

By "drug in amorphous form" is intended the drug when present in the form of molecular clusters, the structural organisation of which is not discernable with X-ray diffraction techniques (PXRD) or by differential scanning calorimetry (DSC). Preferred composites are these which contain at least 75%, or more preferably at least 85% of the drug in amorphous form; composites in which the drug is present at 100% in amorphous form have been obtained with the present invention, and are described in the experimental section.

For "massively dispersed (or in-bulk)" is intended the fact that the drug is deposited not only on the surfaces of the carrier particles, but also inside them: in the present invention the drug is made to diffuse inside carrier particles and stabilised "in situ".

The organic carrier is selected from a cross-linked polymer, a complexing agent or mixtures thereof. The cross-linked polymer is typically water-insoluble, whereas

the complexing agent is typically water-soluble.; the terms "soluble/insoluble" are meant with respect to water at room temperature (20°C); the term "cross-linked" refers to the existence of natural or synthetically induced inter-polymer bonds; a preferred example of an insoluble cross-linked polymer is cross-linked polyvinylpyrrolidone, commercially known as crosspovidone; other examples of polymers of this class are cross-linked sodium-carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene, cross-linked beta-cyclodextrine.

Preferred members of the class of water-soluble complexing agents are cyclodextrines (such as: alpha-, beta-, gamma-cyclodextrine and derivatives thereof), maltodextrine. The complexing agents may contain water molecules of hydration.

The organic carriers used in the present invention are preferably characterised by non high surface area, for example, between 0.05 and 20 m²/g; for example the CL-PVP and cyclodextrine commercially available meet these requirements perfectly, with an average surface area of 0.5-2 m²/g.

The present invention also comprises the use of mixtures of two or more organic carriers: for example the mixture of an water-insoluble cross-linked polymer with a water-soluble complexing agent.

Any active ingredient of pharmaceutical interest (also including mixtures of two or more of them) can be present in the composites claimed by the present invention; drugs sparingly soluble in water are preferred, also known as belonging to the class II of the biopharmaceutical system of classification (cf. *Guidance for Industry: Immediate Release Solid Oral Dosage Forms*, Ed. Centre for Drug Evaluation and Research, FDA, 1997): examples of such compounds are nimesulide, ibuprofen, nifedipine, grisofulvine, piroxicam, progesterone, indomethacine, lorazepam, etc. As shown in the experimental section, it has been possible to obtain high to complete amorphisation of these products (originally present in the crystalline state with low solubility) and their dispersion in-bulk within the carrier.

In the composites according to the invention, the drug and the carrier are present in weight ratios preferably comprised of between 1:0.5 and 1:20, more preferably between 1:1 and 1:10.

The preparation process of the composites constitutes a second subject of the invention. The process comprises mixing the original drug (i.e. the drug in microcrystalline structure to be made amorphous and dispersed within the carrier) with the above mentioned organic carrier, followed by treatment with an oscillating electromagnetic field, at a frequency belonging to the microwave region, with the following particulars:

- (i) the application of the oscillating electromagnetic field is carried out on the previously wetted drug-carrier mixture, or
- (ii) the application of the oscillating electromagnetic field is carried out on the drug-carrier mixture placed in a container constituted of a dielectric material having coupling capacity with microwaves. In both cases a specific heating cycle is applied, as detailed below.

In the first variant (i), the drug-carrier mixture is wetted with an appropriate amount of solvent, until forming a sufficiently dampened mass; the solvent, generally water, is added using known techniques, for example by nebulisation of the solvent through the mixture kept stirring, or simply pouring onto the mixture and mixing it. The solvent is added in an amount comprised of between 0.1 ml/g and 5 ml/g with respect to the dry drug-carrier mixture. The mixture, thus pre-wetted, placed in a reactor (for example a Pyrex glass container), is introduced into the oven and then treated with microwaves at pressure preferably comprised of between 1 and 20 bar.

In variant (ii), the drug-carrier mixture is placed in a sample holder (reactor) made entirely or partially (for example of at least 10%) of a dielectric material coupling with microwaves, and thus introduced into the microwave applicator. For "coupling capacity by microwaves" is intended the fact that the material in question, when exposed to microwaves, increases the temperature in proportion to the power applied; a preferred example of a material having this property is polytetrafluoroethylene loaded with graphite.

Using reactors containing the above mentioned coupling materials, the amorphisation proceeds easily at atmospheric pressure, without the need to operate at high pressure, and without the need to add water or other humectants; that does not preclude however the possibility of adding water and/or operating

under pressure, whenever desired.

In both variants (i) and (ii), the application of the oscillating electromagnetic field is carried out with microwaves having power comprised of between 100 W and 5000 W, for an overall time up to 120 minutes. The oscillating electromagnetic field can indifferently be focussed or non-focussed. The frequency range of the microwaves applied is generally comprised of between 400 MHz and 25000 MHz. The application of the microwaves can take place under conditions of constant or variable power.

The microwave treatment cycle is fundamental according to the present invention. In fact it is required that the microwave power be tuned in such a way that the sample (i.e. the drug-carrier mixture being treated) reaches a temperature value (T°) higher than the melting temperature of the drug contained in the mixture. The temperature T° must then be maintained steady for at least 5 minutes.

There is no specific limit as to how high the temperature T° must be with respect to the drug melting temperature: however it will be preferred to remain rather close to the melting temperature: as a non-limitative indication, T° can be from 1 to 20 degrees C° higher than the drug melting temperature.

By "drug melting temperature" it is meant the temperature corresponding to the peak of the endotherm, as measured by differential scanning calorimetry (DSC), performed at a scanning rate equal to the one set for the dielectric treatment with microwaves.

The microwave treatment can be effected by temporarily setting a specific power level (e.g. 500 W), until the sample reaches the target temperature T° ; the latter can be freely chosen by the operator, provided that it is higher than the melting temperature of the drug present in the mixture; once temperature T° is reached, the treatment is prolonged, tuning (modulating) the microwave power so as to maintain the temperature of the sample steady at the temperature T° , for at least 5 minutes.

Alternatively, it is possible to perform a first step wherein the sample temperature is gradually incremented (for e.g. 10-25 min.), until it reaches the target value T° ; subsequently, the treatment is prolonged, tuning (modulating) the microwave

power so as to maintain the temperature of the sample steady at the temperature T° for at least 5 minutes.

An example of this procedure is illustrated graphically in figure 4, showing the temperature recording for the sample PVP/Nif02, prepared and tested by the Applicant (cf. experimental section, example 1, table 5).

In all circumstances the process is always performed at priority of sample temperature, i.e. not of supplied fixed power: the latter is modulated in order to reach and maintain for at least 5 minutes the pre-set temperature T° in the drug-carrier mixture.

In this respect it is important to remark that a melting substance absorbs energy in irregular way, depending on the relative amount of phases (solid, liquid) it goes through during melting. Therefore a steady administration of electromagnetic energy (microwaves power) during the melting process does not produce a parallel steady temperature in the sample; on the contrary, the thus treated sample inevitably shifts in temperature. In order to maintain the sample at a steady temperature, it is necessary to modulate the microwave power, thus compensating continuously for the variable degree of energy absorption of the sample, which takes place during the fusion process. Such compensations are obtainable by available means of electronic systems capable to detect any changes in the sample temperature and to modify immediately, in excess or defect, the microwave power so as to maintain the sample temperature steady at the pre-set T° value.

The equipment used for the application of the microwaves can be any microwave applicator which operates within the above described intervals and is equipped with suitable means to set the microwave power in function of the sample temperature. Such applicators are known *per se* and already used in the pharmaceutical field for various applications, for example to evaporate solvents. They are generally made up of a microwave generator, a wave guide and an application chamber; the generator is a "magnetron" electronic tube; the wave guide is a corridor, the walls of which are metallic, through a multiple reflection mechanism, they transmit the wave towards the application chamber in which the material is exposed to the microwaves. The applicators are conveniently fitted with

power distribution management and control systems, for the sample temperature and the pressure to which the sample is exposed. Specific examples of the distributors used in the present invention are the Prolabo "Synthewave 402" (monomode applicator for focussed microwaves, freq. 2.45 GHz, max. power. 300 W), or the Mileston "Microsynth" (multimode applicator non-focussed microwaves, with pre-mixing chamber and pyramidal diffuser, maximum power 1000 W).

With respect to what allowed by the known art surface amorphisation, amorphisation in-bulk obtained by the present invention allows great exploitation of the entire volume of the available carrier for the incorporation of the drug in amorphous form: it therefore becomes possible to incorporate into the carrier, significantly greater quantities of amorphous drug with respect to that previously possible. Analogously, with equal amorphous drug content, it is possible to reduce the amount of carrier, thus realising lower volume pharmaceutical formulations (e.g. smaller pills), with important advantages both for the saving of excipient, the economy of the process and packaging, and for the ease of administration and acceptability on the part of the patient.

The composites (stabilised solid dispersions) obtained according to the present invention can be used directly as pharmaceutical compositions and as such administered to patients, or can be added to with excipients and treated according to conventional pharmaceutical techniques with the aim of obtaining pharmaceutical forms suited to different administration needs. For example the composite can be integrated with disintegrants, glidants, lubricants, preservatives, sweeteners, other active ingredients, etc. The preparation procedures of pharmaceutical compositions are known *per se* and comprise for example granulation, compression, film-coating, encapsulation, micro-encapsulation, etc.; the pharmaceutical forms in which the composite can be formulated include granulates for extemporaneous dissolution, pills, mini-pills, capsules, microcapsules, etc.

The present invention will now be described through the following example applications, which do not have limiting function.

EXPERIMENTAL SECTION

Materials and methods

1. Active ingredients

The materials subjected to treatment with microwaves are:

- Ibuprofen, Nimesulide and Nifedipine, representatives of sparingly hydrosoluble drugs, belonging to the biopharmaceutical class II.

The thermal characteristics of Ibuprofen are the following:

Melting temperature $T_m = 75.6\text{ }^{\circ}\text{C}$,

Melting enthalpy $\Delta H_m = 126.6\text{ J/g}$.

The thermal characteristics of Nimesulide are the following:

Melting temperature $T_m = 148.9\text{ }^{\circ}\text{C}$

Melting enthalpy $\Delta H_m = 111.1\text{ J/g}$.

The thermal characteristics of Nifedipine are the following:

Melting temperature $T_m = 172.7\text{ }^{\circ}\text{C}$

Melting enthalpy $\Delta H_m = 101.4\text{ J/g}$.

2. Organic carriers

- Crosspovidone, as an insoluble amphiphilic cross-linked polymer.
- β -cyclodextrine, as a carrier belonging to the class of the hydrosoluble complexing agents.

3. Microwave applicators

- The "Synthewave 402" monomode applicator from Prolabo, operating at a frequency of 2.45 GHz and with a maximum deliverable power of 300 Watts. With this type of applicator the field results as being focused in a restricted spatial volume containing the sample for treatment.
- The "Microsynth" multimode applicator from Milestone fitted with a premixing chamber with a pyramidal microwave diffuser to obtain optimal uniformity of the field. The applicator works with two continuous generation magnetrons (non

pulsed) and distributes a maximum power of 1000 Watts.

Both applicators are equipped with control systems for the delivered power, the developed pressure (up to 20 bar) and the temperature of the sample. The control and monitoring system for the monitoring of the sample temperature is constituted of two types of sensors: one fibre-optic and the other infrared (pyrometer).

4. Characterisation of the physical state of the drug in the composites (degree of dispersion and degree of amorphisation)

The degree of dispersion of the drug in the carrier has been evaluated by SEM-EDS (scanning electronic microscopy and energy dispersion spectroscopy). This technique allows to map, quali-quantitatively, the spatial distribution of single atoms onto the microscope image of the carrier particles; this is done via the acquisition of the X-ray emission spectrum caused by the interaction between the primary electrons and the material. Since it was desired to obtain a quantitative information on the dispersion of amorphous drug within the particles of composite, it was necessary to prepare a section of said particles by a microtome, and to fix it within a epoxy resin matrix. In figure 5 a SEM image of a section of a crospovidone particle is shown.

The percentage of crystalline residue has been calculated using the following relationship:

$$\%C = \frac{(\Delta H_a * 100)}{\text{slope} * T}$$

where %C is the residual percentage crystallinity of the drug, ΔH_a is the apparent specific enthalpy of fusion, determined by DSC, T is the percentage drug content in the system and the constant "slope" represents the angular coefficient of the calibration line obtained by measuring the enthalpy of fusion in drug-carrier physical mixtures pre-constituted with known drug content (as an example see figure 1). The % of drug in the amorphous state (%A) is:

$$\%A = (100\% - \%C)$$

In the following experiments (examples 1-3) a series of drug-carrier mixtures has

been subjected to the amorphisation process according to the present invention.

Example 1

Physically homogeneous mixtures of Ibuprofen with β -cyclodextrine hydrate and Ibuprofen with Crosspovidone in weight ratios of 1 to 9 have been prepared; approx. 5 grams of the mixture, for each test, have been inserted into a Pyrex glass reactor (a material non-coupling with the microwaves) inside the applicator of the monomode oven. To each mixture, appropriately kept stirring by a mechanical stirrer in Pyrex glass (operating at 3 revolutions per minute), has been added an amount of purified water equal to 1 ml per gram of β -cyclodextrine (samples Beta/Ibu13, Beta/Ibu14, Beta/Nim01, Beta/Nim03) or 2 ml per gram of Crosspovidone (samples PVP/Ibu01, PVP/Ibu02, PVP/Nim01), or 3 ml per gram of Crosspovidone (samples PVP/Nim02, PVP/Nim03, PVP/Nim04, PVP/Nif02). The wet mixtures have then been subjected to treatment with microwaves at programmed temperature and at atmospheric pressure under the operative conditions reported in tables 1 and 2.

For irradiation, a monomode "Synthewave 402" applicator from Prolabo has been used, operating at a frequency of 2.45 GHz and with a maximum deliverable power of 300 Watts.

The results obtained are illustrated in the two following tables.

Table 1: operative conditions of the process and values of residual crystallinity of the Ibuprofen β -cyclodextrine composites obtained with the monomode applicator.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (*) (%)
Beta/Ibu13	10	From 25 °C to 90 °C in 15' & 10' at 90 °C	25	22.7

Beta/Ibu14	10	From 25 °C to 90 °C in 15' & 20' at 90 °C	35	21.6
------------	----	--	----	------

(*) % of crystallinity with respect to the crystallinity of the original drug (=100%).

Table 2: operative conditions of the process and residual crystallinity values of the Ibuprofen Crosspovidone composites obtained with the monomode applicator.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Ibu01	10	From 25 °C to 90 °C in 15' & 10' at 90 °C	25	0.0
PVP/Ibu02	10	From 25 °C to 80 °C in 15' & 15' at 80 °C	30	0.0

The same approach has been used with a drug having different thermal characteristics to the previous (Nimesulide, $T_m = 148.9$ °C, $\Delta H_m = 111.1$ J/g). The method variations and the crystallinity data are reported in tables 3 and 4.

Table 3: operative conditions of the process and residual crystallinity values of the Nimesulide β -cyclodextrine composites obtained with a monomode applicator.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
Beta/Nim01	10	From 25 °C to 160 °C in 20' & 10' at 160 °C	30	32.0
Beta/Nim03	10	From 25 °C to 160 °C in 20' & 20' at 160 °C	40	40.7

Table 4: operative conditions of the process and residual crystallinity values of the Nimesulide Crosspovidone composites obtained with a monomode applicator.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Nim01	10	From 25 °C to 150 °C in 20' & 10' at 150 °C	30	45.4
PVP/Nim02	10	From 25 °C to 150 °C in 20' & 10' at 150 °C	30	39.4
PVP/Nim03	16.7	From 25 °C to 150 °C in 15' & 15' at 150 °C	30	38.0
PVP/Nim04	16.7	From 25 °C to 150 °C in 15' & 30' at 150 °C	45	36.6

The same process has been used with Nifedipine, using the "Microsynth" multimode applicator. The process parameters and the crystallinity characteristics are reported in table 5.

Table 5: operative conditions of the process and residual crystallinity values of the Nifedipine Crosspovidone composite obtained with the multimode applicator.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Nif02	16.7	From 25 °C to 175 °C in 15' & 10' at 175 °C	35	0.0

The graphic registration of the sample temperature in this test is shown in figure 4. The low or zero residual crystallinity percentages observed in the examples shown demonstrate the achievement of high grades of amorphisation. In particular, in the case of ibuprofen and nifedipine, composites characterised by complete

amorphisation of the drug (0% residual crystallinity) are obtained.

Assessment of drug dispersion within the carrier matrix

The in-bulk dispersion of the active principle was confirmed by SEM-EDS observations, as follows.

The presence of sulphur was quantitatively assessed in an area of the section of the particle of PVP/Nim 02m, shown in figure 6. Sulphur, which is part of the drug molecule (nimesulide), and not of the carrier (crospovidone), was searched in three points located at growing distance from the surface of the particle, marked with numbers 1,2,3 in figure 6. As evident from the X ray spectra shown in the box of figure 6, the sulphur atom was detected in high amounts in all points, thus proving the presence of the drug also inside the polymeric carrier. The inner part of the section shows the homogeneity typical of a solid dispersion (amorphous drug dispersed within the amorphous polymer matrix).

This demonstrates that a massive dispersion (in-bulk) of the amorphised drug is achieved, i.e. not only on the surfaces of the carrier particles, but deep within them.

A further demonstration of the in-bulk dispersion of the drug is obtained via the following calculation:

considering that the drug/polymer weight ratio used in the preceding experiments is equal to 1:5, (PVP/Nim 04) the mass balance of the composite is:

$$M_T = M_{DC} + M_{DA} + M_C$$

wherein: M_{DC} represents the mass of the crystalline drug in the composite, M_{DA} the mass of the amorphous drug, M_C the mass of the carrier and M_T the total mass.

For the examples reported, it will be:

$$M_{DC} = 206.4mg * 0.366 = 75.5,$$

$$M_{DA} = 206.4mg - 75.5mg = 130.9,$$

$$M_C = 1028.9mg \text{ and } M_T = 1235.4mg.$$

Since the PVP-CL used has a specific surface area of 4.5 m²/g (values determined experimentally by adsorption isotherms method B.E.T.) the weight fraction

contained in the composite has a total surface development equal to $4.5 * 0.833 = 3.75 \text{ m}^2/\text{g}$.

Reasonably, the drug molecules which can be stabilised in amorphous form on the surfaces of carriers constitute a molecular monolayer interacting with the surfaces themselves.

The drug molecule can interact with the molecules of polyvinylpyrrolidone, which are present on the surfaces of the carrier, with interactions which are either hydrophobic or hydrophilic in nature (remembering the amphiphilic nature of the polymer used); estimating the molecular surface development of the nimesulide, characterised by these two interactions, one can calculate the area occupied by a single molecule interacting with the surface.

Using the three dimensional molecular structure of nimesulide, minimised with both molecular mechanical (MMFF force field) and semi-empirical (AM1) algorithms with the software "Spartan 02", the two molecular descriptors involved can be calculated (molecular surface area with hydrophobic characteristics and molecular surface area with hydrophilic characteristics). The measurement of these descriptors has been performed with the molecular prediction software "QikProp" and has given the following values:

hydrophobic molecular surface area = 0.9 nm^2

hydrophilic molecular surface area = 1.75 nm^2

Considering the two contributions, the surface covered by a single molecule of nimesulide is equal to 2.65 nm^2 .

The quantity of molecules necessary to constitute an amorphous monolayer on the surface of the carrier will be given by $3.75 \text{ m}^2\text{g}^{-1} / 2.65 \cdot 10^{-18} \text{ m}^2 = 140.7 \cdot 10^{16}$ molecules, i.e. 0.721 mg of nimesulide. Rewriting the equation to balance with these values for M_{DA} , one obtains a value of $M_{DC} = 205.7 \text{ mg}$ equal to 99.6% of crystallinity.

Hence, one can conclude that the excess of amorphous drug involved in preparation PVPNIM02 is found dispersed to a large measure inside (in-bulk) the carrier particles.

Example 2

Homogeneous physical mixtures of Nimesulide with Crosspovidone and β -cyclodextrine have been prepared in weight ratios 1 to 2 and 1 to 5, physical mixtures of Nifedipine with Crosspovidone 1 to 5 (w/w); approx. 5 grams of the mixture, for each test, have been inserted into a PTFE container loaded with graphite and then placed inside the application chamber of a multimode "Microsynth" oven (Milestone). In addition, a 1 to 9 Ibuprofen β -cyclodextrine mixture has been prepared and treated in the same oven, setting the power of the oven to a fixed and constant value, for the time of treatment, equal to 600 Watts. Water has not been added and the reaction environment has been maintained at atmospheric pressure (1 atm).

The process conditions and the physical characteristics of the composites obtained are reported in table 6.

Table 6: operative conditions of the process and residual crystallinity values of the Nimesulide β -cyclodextrine, Ibuprofen β -cyclodextrine, Nimesulide Crosspovidone and Nifedipine Crosspovidone composites obtained with the multimode applicator.

Samples	(w/w) ^a	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Nim05	1 to 2	From 25 °C to 150 °C in 10' & 10' at 150 °C	30	27.3
PVP/Nif04	1 to 5	From 25 °C to 175 °C in 15' & 10' at 175 °C	25	1.0
Betalbu15	1 to 9	600 W up to 80°C & 5' at 80°C	5	23.8
Betalbu16	1 to 9	600 W up to 80°C & 3' at 80°C	3	38.4

(a) = weight ratio between drug and carrier

The residual crystallinity values indicate also in this case a high degree of amorphisation of the drug. The distribution in-bulk of the drug has been confirmed with the above described methods.

Example 3

A mixture of Nimesulide/Crosspovidone in a weight ratio of 1 to 5 has been prepared; approx. 6 grams of mixture have been inserted into the reactor of the multimode applicator. To the mixture have been added approx. 10 ml of purified water. The mixture, thus wetted, has been subjected to treatment with microwaves at temperature program temperature and at increasing pressure according to the phase diagram of water (at constant volume): from 1 bar (at T=25 °C) up to 5 bar (at T=155 °C).

The process conditions and the residual crystallinity obtained are reported in the following table 7:

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Nim07	16.7	From 25 °C to 155 °C in 10' & 10' at 155 °C and P=5 bar	25	45.0

Example 4 (reference) To verify the criticality of the treatment used in the present invention, a Nimesulide-Crosspovidone physical mixture has been prepared in the weight ratio 1 to 5; approx. 2 grams of mixture have been introduced into a general reactor (in Pyrex glass) inside a monomode applicator. Differently from that requested in the present invention, the reactor used is not based on dielectric materials coupling with the microwaves. The mixtures thus obtained have been successively subjected to treatment with microwaves at temperature program temperature and at reduced pressure ($0.1 \cdot 10^5$ Pa) under the operative conditions reported in the table 8.

Table 8: operative conditions and residual crystallinity values of Nimesulide-Crosspovidone composites.

Samples	Drug content (%)	Temperature program	Total time (minutes)	Residual crystallinity (%)
PVP/Nim06	16.7	From 25 °C to 150 °C in 10' & 15' at 150 °C	25	96.0
PVP/Nif01	16.7	From 25 °C to 170 °C in 10' & 15' at 170 °C	25	97.5

As is clear from the data of the percent residual crystallinity (96-97%), the treatment has not been able to obtain any amorphisation: the drug maintains its crystallinity substantially unaltered. These data demonstrate that, when operating in dry conditions, in the absence of reactors coupling with the microwaves, it is not possible to obtain any dispersion of amorphised drug. In figures 2 and 3 are shown the temperature profiles of the two reference samples during the treatment cycle: as is clear from the figures, both mixtures treated do not have significant temperature increases such as to induce solid-liquid transitions in the crystalline drugs, despite using the maximum power of the applicator used; that further confirms the absence of amorphisation of drug under these experimental conditions.

Example 5 (reference)

In this example a drug-carrier mixture was dry-treated with microwaves; differently from the invention, linear polyvinylpyrrolidone was used as a carrier, which is neither a cross-linked polymer, or a complexing agent; the power applied was maintained constant throughout the entire treatment, following the teaching of the prior art, e.g. example 1 of EP 1308156.

Thus 1 g of Nifedipine and 5 g of polyvinylpyrrolidone K30 were put into a teflon reactor and treated with microwaves for 4 minutes at a power of 630 W. The residual crystallinity of the thus treated material, determined by DSC, was 93.2 %. Accordingly, less than 7% of the drug was converted into amorphous form.

Example 6 (reference)

In this example the sample was wet-treated with microwaves, using nifedipine as a drug and cross-linked polyvinylpyrrolidone as a carrier; differently from the invention, the power applied was maintained constant throughout the entire treatment following the teaching of the prior art, e.g. example 4 of US 6462093.

Thus, 1.25 g of water were added to a mixture made of 1 g of Nifedipine and 5 g of crospovidone in a teflon reactor and treated with microwaves (2.45 GHz) with a power of 700 W for 20 minutes. After 5 minutes the treatment was suspended because the mixture was completely decomposed leaving only a carbonised residue. The same tests was repeated using only crospovidone without adding water. After about 10 minutes of treatment at 700 W the material was completely carbonised as in the previous test. This phenomenon is presumably due to a "thermal runaway" caused by a sudden increase of the imaginary part of complex permittivity (loss factor) with temperature. Such increase result in a growing dielectric coupling and thus a further increase in the sample temperature (for a review on these phenomena cf. Committee on microwave processing of materials: an emerging industrial technology. Microwave processing of materials, pag. 36, Publication NMAB-473. Washington: National academy Press, 1994).

CLAIMS

- 1) A composite containing a drug dispersed in an organic carrier selected from a complexing agent or a cross-linked polymer and mixtures thereof, wherein the drug is massively dispersed (in-bulk) within the composite, and is present in amorphous form in a quantity greater than or equal to 50 % by weight, with respect to the total of drug present in the composite.
- 2) The composite according to claim 1, in which the drug and the carrier are present in weight ratios comprised of between 1:0.5 and 1:20.
- 3) The composite according to claim 2, in which the drug and the carrier are present in weight ratios comprised of between 1:1 and 1:10.
- 4) The composite according to claims 1-3, in which the cross-linked polymer is selected from cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, cross-linked starch, cross-linked dextran, cross-linked polystyrene, cross-linked β -cyclodextrine.
- 5) The composite according to claims 1-4, in which the complexing agent is selected from alpha-cyclodextrine, beta-cyclodextrine, gamma-cyclodextrine, derivatives thereof, maltodextrine.
- 6) The composite according to claims 1-5, in which said organic carrier has a surface area comprised of between 0.05 m²/g and 20 m²/g.
- 7) The composite according to claims 1-6, in which said drug is a drug sparingly soluble in water.
- 8) The composite according to claim 7, in which said drug is selected from nimesulide, ibuprofen, nifedipine, griseofulvine, piroxicam, progesterone, lorazepam.

- 9) The composite as described in the claims 1-8, for use in therapy.
- 10) A pharmaceutical composition containing the composite described in claims 1-8, optionally associated with pharmaceutically acceptable excipients.
- 11) The pharmaceutical composition according to claim 10, formulated as a granulate, pill, mini-pill, capsule, micro-capsule.
- 12) A process for the preparation of the composite described in claims 1-8, comprising the following steps:
- a) forming a wet mixture of said drug and said organic carrier;
 - b) irradiating the mixture obtained in a), with microwaves such that the mixture is heated to a temperature higher than the melting temperature of the drug, and such temperature is thus maintained for at least 5 minutes.
- 13) The process according to claim 12, in which said wet mixture is formed by adding water to the carrier-drug composite in a quantity comprised of between 0.1 ml/g and 5 ml/g with respect to the dry mixture of the composite.
- 14) The process according to the claims 12-13, in which the pressure at which the irradiation is carried out is comprised of between 1 and 20 bar.
- 15) The process according to the claims 12-14, in which the irradiation with microwaves is carried out in a power range comprised of between 100 W and 5000 W for an overall time up to 120 minutes.
- 16) A process for the preparation of the composite described in the claims 1-8, comprising the following steps:
- a) mixing together said drug and said organic carrier;
 - b) placing the mixture obtained in a) in a container constituted of a dielectric material having coupling capacity with the microwaves;
 - c) irradiating with microwaves the container containing said mixture, such that the

mixture is heated to a temperature higher than the melting temperature of the drug, and such temperature is maintained for at least 5 minutes.

17) The process according to claim 16, in which said dielectric material is polytetrafluoroethylene loaded with graphite.

18) The process according to the claims 16-17, in which the irradiation with microwaves is carried out in an power range comprised of between 100 W and 5000 W, for an overall time up to 120 minutes.

19) A composite obtainable through the process described in the claims 12-18.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5





FIGURE 6



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



10/540139

(43) International Publication Date
8 July 2004 (08.07.2004)


PCT

(10) International Publication Number
WO 2004/056340 A3

- (51) International Patent Classification⁷: **A61K 9/14**
- (21) International Application Number:
PCT/EP2003/014740
- (22) International Filing Date:
22 December 2003 (22.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
MI2002A002748
23 December 2002 (23.12.2002) IT
- (71) Applicant (for all designated States except US): **EURAND S.P.A.** [IT/IT]; Via Martin Luther King 13, I-20060 Pesano Con Bornago (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **COLOMBO, Italo** [IT/IT]; Via Don Sturzo, 15, I-20065 Inzago (IT). **GERVASONI, Dario** [IT/IT]; Via Alberti 8, I-20061 Carugate (IT).
- (74) Agent: **GERVASI, Gemma; Notarbartolo & Gervasi S.p.A.**, Corso di Porta Vittoria 9, I-20122 Milan (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report

[Continued on next page]

(54) Title: STABILISED SOLID DRUG DISPERSIONS IN AN ORGANIC CARRIER AND A PROCESS FOR PREPARING THE SAME



(57) Abstract: New solid drug dispersions are described in which the drug is present in amorphous form and massively dispersed (in bulk) inside the particles of an organic carrier selected from cross-linked polymers and/or a complexing agents. These dispersions are obtainable by mixing together the drug and the carrier and applying an oscillating electromagnetic field to the mixture, to a frequency belonging to the microwave region; the microwaves are applied according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes. With respect to the known techniques, the present invention allows to increase in the amount of drug incorporated into the carrier in amorphous form, and to increase the physical stability of the amorphous phase. This is particularly useful in the preparation of pharmaceutical compositions based on drugs which are crystalline in nature, such as are notoriously sparingly soluble in water: thanks to the increased amounts and stability of the drug in amorphous form, the resulting formulations have a more rapid and intense effect, and are endowed with greater bioavailability.

WO 2004/056340 A3



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:
11 November 2004

INTERNATIONAL SEARCH REPORT

International Application No.

PC 03/14740

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 1 308 156 A (EISAI CO. LTD., JP) 7 May 2003 (2003-05-07) cited in the application claims examples page 2, paragraph 8 page 2, paragraph 11 page 3, line 9 - page 4, line 8 page 5, paragraph 34 page 5, paragraph 39	1-4,6-11
X	& WO 02/13792 A (EISAI CO. LTD., JP) 21 February 2002 (2002-02-21) ----- -/--	1-4,6-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

17 September 2004

Date of mailing of the international search report

01/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/03/14740

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 462 093 B1 (M. MIYAMOTO ET AL.) 8 October 2002 (2002-10-08) cited in the application claims examples column 3, line 9 - line 21 column 3, line 39 - line 62 column 4, line 43 - line 52 column 5, line 17 - line 64 column 6, line 27 - line 42 column 6, line 56 - line 65 column 7, line 11 - column 8, line 42 -----	1-11
X	DATABASE WPI Section Ch, Week 199351 Derwent Publications Ltd., London, GB; Class A96, AN 1993-408839 XP002296809 & JP 05 306225 A (TAIYO YAKUHHIN KOGYO KK) 19 November 1993 (1993-11-19) abstract -----	1-4,6-11
X	WO 98/00113 A (SCHERING) 8 January 1998 (1998-01-08) claims page 3, line 37 - page 4, line 6 page 4, line 29 - page 5, line 3 page 5, line 13 - line 31 sentence 1 - sentence 14 page 8, line 15 - line 20 examples 17,18 -----	1-4,6-11
X	US 5 972 381 A (S.A. SANGEKAR ET AL.) 26 October 1999 (1999-10-26) claims examples 17,18 -----	1-4,6-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/14740

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1308156	A	07-05-2003	CA 2418490 A1 EP 1308156 A1 WO 0213792 A1 US 2003099703 A1	21-02-2002 07-05-2003 21-02-2002 29-05-2003
WO 0213792	A	21-02-2002	CA 2418490 A1 EP 1308156 A1 WO 0213792 A1 US 2003099703 A1	21-02-2002 07-05-2003 21-02-2002 29-05-2003
US 6462093	B1	08-10-2002	AT 255405 T AU 702088 B2 AU 6669396 A CA 2228907 A1 CN 1192677 A ,B CZ 9800326 A3 DE 69630964 D1 EP 1356807 A2 EP 0852140 A1 WO 9706781 A1 NO 980549 A NZ 315089 A RU 2167649 C2 TW 487582 B	15-12-2003 11-02-1999 12-03-1997 27-02-1997 09-09-1998 17-06-1998 15-01-2004 29-10-2003 08-07-1998 27-02-1997 02-04-1998 29-06-1999 27-05-2001 21-05-2002
JP 5306225	A	19-11-1993	JP 2516524 B2	24-07-1996
WO 9800113	A	08-01-1998	AT 273002 T AU 3483497 A CA 2258679 A1 DE 69730241 D1 EP 0954288 A1 JP 2000514057 T WO 9800113 A1	15-08-2004 21-01-1998 08-01-1998 16-09-2004 10-11-1999 24-10-2000 08-01-1998
US 5972381	A	26-10-1999	NONE	